NasdaqCM - Delayed Quote USD
MoonLake Immunotherapeutics (MLTX)
37.62
-0.04
(-0.11%)
At close: May 16 at 4:00:00 PM EDT
37.62
0.00
(0.00%)
After hours: May 16 at 4:05:08 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jorge Santos da Silva Ph.D. | Co-Founder, CEO & Director | 1.3M | -- | 1977 |
| Dr. Kristian Reich M.D., Ph.D. | Co-Founder & Chief Scientific Officer | 1.3M | -- | 1966 |
| Mr. Matthias Bodenstedt | Chief Financial Officer | 987.87k | -- | 1988 |
| Mr. Oliver Daltrop Ph.D. | Chief Operations Officer | -- | -- | -- |
| Ms. Carla Bretes | Director of Investor Relations & External Communications | -- | -- | -- |
| Mr. Nicolas Mosimann Ph.D. | General Counsel | -- | -- | -- |
| Joana Cortez | Senior Director Legal & Compliance | -- | -- | -- |
| Tino Anthamatten | Vice President of Marketing, Market Access & Pricing | -- | -- | -- |
| Luciana Marques | Director of HR, People & Culture | -- | -- | -- |
| Ms. Nuala Brennan | Chief Clinical Development Officer | -- | -- | -- |
MoonLake Immunotherapeutics
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 100
Description
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Corporate Governance
MoonLake Immunotherapeutics’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
August 5, 2025 at 12:30 PM UTC - August 11, 2025 at 12:30 PM UTC
MoonLake Immunotherapeutics Earnings Date
Recent Events
Related Tickers
PTGX Protagonist Therapeutics, Inc.
44.49
+0.18%
APGE Apogee Therapeutics, Inc.
40.62
-0.05%
RVMD Revolution Medicines, Inc.
39.54
+0.25%
MRUS Merus N.V.
41.56
+3.69%
EWTX Edgewise Therapeutics, Inc.
14.78
+2.28%
SRRK Scholar Rock Holding Corporation
30.55
-0.91%
AKRO Akero Therapeutics, Inc.
38.87
-2.73%
CYTK Cytokinetics, Incorporated
31.00
+3.89%
SLNO Soleno Therapeutics, Inc.
75.01
-0.08%
VRDN Viridian Therapeutics, Inc.
12.94
+2.54%